To evaluate the efficacy of hysteroscopy-assisted laparoscopy as a treatment strategy for type 2 cesarean scar pregnancy at gestational age >8 weeks. Design: Retrospective case series (Canadian Task Force classification II-3). Setting: A tertiary hospital. Patients: Eight women with type 2 cesarean scar pregnancy at a gestational age >8 weeks. Interventions: All patients underwent hysteroscopy-assisted laparoscopic resection and isthmus repair of cesarean scar pregnancy. Measurements and Main Results: All patients underwent removal of the cesarean scar pregnancy and complete repair of the uterine scar defect. The median operative time was 123.0 minutes (range, 100−168 minutes), median blood loss was 65.0 mL (range, 20−100 mL), and median length of hospital stay was 9.1 days (range, 8−12 days). There were no adverse reactions. The mean time to serum b-human chorionic gonadotropin (b-HCG) resolution was 22.9 days (range, 14−30 days), and menstruation resumed after 9 to 15 days with serum b-HCG returning to nondetectable levels. There was no recurrence of cesarean scar pregnancy at long-term follow-up. Conclusion: Hysteroscopy-assisted laparoscopy may be an effective treatment for patients with type 2 cesarean scar pregnancy at gestational age >8 weeks.

The findings from this study indicated that the upregulation of miR-219 decreases LTP inhibition and hippocampal neuronal cell apoptosis in T2DM mice by downregulating the NMDAR signaling pathway, therefore suggesting that MiR-219 might be a future therapeutic strategy for T2DM.